Recently, pembrolizumab (anti PD-1) used in 30 patients affected by classic and endemic Kaposi’s sarcoma showed effective anti-tumor activity with an acceptable safety profile, as cardiac treatment-related adverse events occurred in 6% (acute HF) and discontinuation was required in two (12%, due to acute reversible HF) [49]. Here, PDCD1 is linked to Kaposi's sarcoma.